3P Biopharmaceuticals (now 3PBIOVIAN)

Pamplona-Noáin, Spain
Biologics (microbial & mammalian) AAV Adenoviral Lentiviral Cell Therapy Plasmid DNA Recombinant Proteins Biosimilars Fill/Finish (recombinant proteins & viral vectors)
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: 3P Biopharmaceuticals (now 3PBIOVIAN)

Signal Score
60.0/100
Quality Compliance
Assessment pending
Headquarters
Pamplona-Noáin, Spain
Modalities
Biologics (microbial & mammalian), AAV, Adenoviral, Lentiviral, Cell Therapy, Plasmid DNA, Recombinant Proteins, Biosimilars, Fill/Finish (recombinant proteins & viral vectors)
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About 3P Biopharmaceuticals (now 3PBIOVIAN)

Auto-created by AI matchmaker. Data verification pending.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesBiologics (microbial & mammalian), AAV, Adenoviral, Lentiviral, Cell Therapy, Plasmid DNA, Recombinant Proteins, Biosimilars, Fill/Finish (recombinant proteins & viral vectors)
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 60.0
Broad modality coverage (9 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Broad modality coverage (9 modalities)
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Biologics (microbial & mammalian) CDMOs → AAV CDMOs → Adenoviral CDMOs → Lentiviral CDMOs → Cell Therapy CDMOs → Plasmid DNA CDMOs → Recombinant Proteins CDMOs → Biosimilars CDMOs → Fill/Finish (recombinant proteins & viral vectors) CDMOs →

Similar CDMOs

Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
Signal Score: 83.1
AAV, Lentiviral, Plasmid DNA, Adenoviral
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 91.7
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 80.6
CAR-T, Cell Therapy, AAV, Lentiviral
OmniaBio
Hamilton, ON
Signal Score: 79.5
AAV, Lentiviral, CAR-T, Cell Therapy
Lonza
Basel, Switzerland
Signal Score: 78.2
AAV, Lentiviral, Cell Therapy, mRNA